Q-omics provides the consensus-scored PRELID3A profile across patient tissues and cancer cell-line models. PRELID3A expression is associated with patient survival in 27 of 34 cancer types, with the highest sampling consensus in KIRC. Among the 18 cancer types available for tumor–normal comparison, PRELID3A is differentially expressed in 13, with the highest sampling consensus in HNSC. Additionally, PRELID3A RNA expression shows 18,676 significant gene co-expression associations, with the highest sampling consensus in UVM. Together, these results highlight KIRC, HNSC, and UVM as cancer lineages where PRELID3A shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for PRELID3A — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes PRELID3A survival associations across molecular data types. PRELID3A RNA expression shows survival associations in the most cancer types (27), followed by mass-spec protein abundance (1). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible PRELID3A RNA expression–survival associations across cancer types. High PRELID3A expression shows unfavorable associations in KIRC, KIRP, UCEC, MESO, ACC and CESC. The KIRC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify KIRC as the clearest survival context for PRELID3A RNA expression.
This table summarizes PRELID3A tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 13. The strongest signals are observed in HNSC for RNA.
This table ranks reproducible tumor–normal expression differences for PRELID3A. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. PRELID3A shows higher tumor expression in HNSC, COAD, KIRP, KIRC, THCA and LUSC. The HNSC box plot shows higher PRELID3A RNA expression in tumor versus normal tissue (log2 FC = +1.488, t-test p < 0.001).
This table shows molecular features associated with PRELID3A in patient tissues and cancer cell lines. In patient samples, PRELID3A shows the broadest associations at the RNA and protein expression levels, with UVM recurring as the lineage with the largest associated feature set. In cancer cell lines, PRELID3A RNA and mutation anchors are most strongly linked to RNA-expression features, especially in LUNG_NSCLC_LUAD, while CRISPR and shRNA rows add functional-dependency signals in LARGE_INTESTINE and BLOOD_Lymphoma.
